Aliskiren-treated type 2 diabetes patients with comorbid kidney or heart disease did not show lower rates of heart attack, stroke or death from cardiovascular and renal disease-related causes at 2.5 years compared with the placebo group, a study indicated. Aliskiren treatment was linked to lower systolic and diastolic blood pressures and higher average decreases in urinary albumin-to-creatinine ratio, but increased incidence of hyperkalemia and hypotension, compared with placebo therapy. The results were presented at Kidney Week 2012 and published in the New England Journal of Medicine.